D
David Back
Researcher at University of Liverpool
Publications - 597
Citations - 23040
David Back is an academic researcher from University of Liverpool. The author has contributed to research in topics: Ritonavir & Saquinavir. The author has an hindex of 76, co-authored 586 publications receiving 21838 citations. Previous affiliations of David Back include Rega Institute for Medical Research & University of Vienna.
Papers
More filters
Journal ArticleDOI
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Jacques Fellay,Catia Marzolini,Emma R. Meaden,David Back,Thierry Buclin,Jean Philippe Chave,Laurent A. Decosterd,Hansjakob Furrer,Milos Opravil,Giuseppe Pantaleo,Dorota Retelska,Lidia Ruiz,Alfred H. Schinkel,Pietro Vernazza,Chin B. Eap,Amalio Telenti +15 more
TL;DR: The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment, which suggests that P-glycoprotein has an important role in admittance of antifiltration drugs to restricted compartments in vivo.
Journal ArticleDOI
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
V.A. Eagling,David Back,M. Barry +2 more
TL;DR: The HIV protease inhibitors have differential effects on CYP isozymes and there is obvious potential for clinically significant drug interactions particularly with ritonavir.
Journal ArticleDOI
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
TL;DR: In this article, the authors evaluate the selectivity and rank the order of potency of a range of iso-form-selective CYP inhibitors and compare directly the effects of these inhibitors in human and rat hepatic microsomes.
Journal ArticleDOI
Darunavir: pharmacokinetics and drug interactions.
TL;DR: Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.
Journal ArticleDOI
Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
TL;DR: Drug interactions are likely to remain one of the major considerations when selecting a therapeutic regimen for patients with HIV, and the regimen of choice consists of 2 nucleoside analogues plus a protease inhibitor with high in vivo efficacy.